Steven Mittelman, MD, PhD

Dr. Steven Mittelman is interested in understanding how obesity worsens cancer outcomes, specifically in children with acute lymphoblastic leukemia (ALL). He investigates the relationships between adipocytes and ALL cells, evaluating effects on chemotherapy pharmacokinetics, cancer metabolism and treatment resistance. His research primarily involves cell culture, pre-clinical models and human samples.

Orgel E, Mueske NM, Wren TA, Gilsanz V, Butturini AM, Freyer DR, Mittelman SD. Early injury to cortical and cancellous bone from induction chemotherapy for adolescents and young adults treated for acute lymphoblastic leukemia. Bone. 2016 Apr;85:131-7. doi: 10.1016/j.bone.2016.01.027. Epub 2016 Feb 3.

Sheng X, Tucci J, Parmentier JH, Ji L, Behan JW, Heisterkamp N, Mittelman SD. Adipocytes cause leukemia cell resistance to daunorubicin via oxidative stress response. Oncotarget. 2016 Nov 8;7(45):73147-73159. doi: 10.18632/oncotarget.12246.

Orgel E, Mueske NM, Sposto R, Gilsanz V, Freyer DR, Mittelman SD. Limitations of body mass index to assess body composition due to sarcopenic obesity during leukemia therapy. Leuk Lymphoma. 2016 Jan 27:1-8. doi: 10.3109/10428194.2015.1136741. [Epub ahead of print]

Parmentier JH, Maggi M, Tarasco E, Scotti C, Avramis VI, Mittelman SD. Glutaminase activity determines cytotoxicity of L-asparaginases on most leukemia cell lines. Leuk Res. 2015 Jul;39(7):757-62. doi: 10.1016/j.leukres.2015.04.008. Epub 2015 Apr 22.

Orgel E, Tucci J, Alhushki W, Malvar J, Sposto R, Fu CH, Freyer DR, Abdel-Azim H, Mittelman SD. Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia. Blood. 2014 Dec 18;124(26):3932-8. doi: 10.1182/blood-2014-08-595389. Epub 2014 Oct 27.